Matthew M. Mirsky - Publications

Infliximab for the Treatment of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 29, 2026

CRE26-052: Metastatic Salivary Clear Cell Carcinoma With Response to Checkpoint Inhibition: Case Report and Review of the Literature.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

HSR26-208: Disparities in Definitive Treatment for Older Adults With Early-Stage Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

HSR26-208: Disparities in Definitive Treatment for Older Adults With Early-Stage Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

CRE26-052: Metastatic Salivary Clear Cell Carcinoma With Response to Checkpoint Inhibition: Case Report and Review of the Literature.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Cerebrovascular Accident Risk in Survivors of Head and Neck Cancer: JACC CardioOncology State-of-the-Art Review.

Journal: JACC. CardioOncology

Published: December 04, 2025

Immune-related adverse events, survival outcomes, and next steps in patients with stage III melanoma: real-world experience at a National Cancer Institute-designated Comprehensive Cancer Center.

Journal: The oncologist

Published: September 28, 2025

Systemic Therapy for Operable NSCLC: A Review of the Literature and Discussion of Future Directions.

Journal: Journal of clinical medicine

Published: April 26, 2025

Outcomes in patients with multiple sclerosis and solid organ cancers treated with immune checkpoint inhibitors.

Journal: Neuro-oncology advances

Published: April 23, 2025

A single-institution study evaluating the fertility of young adults with malignancy treated with immunotherapy.

Journal: The oncologist

Published: March 29, 2025

Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 22, 2024

Epidermal Growth Factor Receptor Kinase Domain Duplication in Lung Adenocarcinoma with Response to Osimertinib: A Case Report and Literature Review.

Journal: Case reports in oncology

Published: November 08, 2024